BR112021020265A2 - Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo - Google Patents
Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduoInfo
- Publication number
- BR112021020265A2 BR112021020265A2 BR112021020265A BR112021020265A BR112021020265A2 BR 112021020265 A2 BR112021020265 A2 BR 112021020265A2 BR 112021020265 A BR112021020265 A BR 112021020265A BR 112021020265 A BR112021020265 A BR 112021020265A BR 112021020265 A2 BR112021020265 A2 BR 112021020265A2
- Authority
- BR
- Brazil
- Prior art keywords
- hematologic malignancy
- treating
- binding
- subject
- diabody
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 6
- 201000005787 hematologic cancer Diseases 0.000 title abstract 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo. a presente invenção é direcionada a um regime de dosagem para administrar um diacorpo bispecífico cd123 x cd3 para pacientes com uma malignidade hematológica, tal como leucemia mieloide aguda (aml) ou síndrome mielodisplástica (mds). a presente invenção também é direcionada a um regime de dosagem para administrar um diacorpo bispecífico cd123 x cd3 em combinação com uma molécula capaz de ligar pd-1 ou um ligante natural de pd-1 (uma molécula de ligação de pd-1 ou de ligante de pd-1) a pacientes com uma malignidade hematológica, tal como leucemia mieloide aguda (aml) ou síndrome mielodisplástica (mds). a invenção diz respeito, particularmente, ao uso de tais regimes para administrar o diacorpo bispecífico cd123 x cd3 de sequência otimizada, dart-a, que é capaz da ligação simultânea a cd123 e cd3.]
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831979P | 2019-04-10 | 2019-04-10 | |
US201962831969P | 2019-04-10 | 2019-04-10 | |
US201962929381P | 2019-11-01 | 2019-11-01 | |
US201962929401P | 2019-11-01 | 2019-11-01 | |
US202063001388P | 2020-03-29 | 2020-03-29 | |
PCT/US2020/027140 WO2020210277A1 (en) | 2019-04-10 | 2020-04-08 | Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021020265A2 true BR112021020265A2 (pt) | 2022-01-11 |
Family
ID=72751774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021020265A BR112021020265A2 (pt) | 2019-04-10 | 2020-04-08 | Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220213203A1 (pt) |
EP (1) | EP3953391A1 (pt) |
JP (1) | JP2022526640A (pt) |
KR (1) | KR20210149807A (pt) |
CN (1) | CN113728009A (pt) |
AU (1) | AU2020272734A1 (pt) |
BR (1) | BR112021020265A2 (pt) |
CA (1) | CA3136255A1 (pt) |
IL (1) | IL287095A (pt) |
MX (1) | MX2021012263A (pt) |
SG (1) | SG11202111192TA (pt) |
TW (1) | TW202104263A (pt) |
WO (1) | WO2020210277A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4341291A1 (en) * | 2021-05-21 | 2024-03-27 | Aptevo Research and Development LLC | Dosing regimens for protein therapeutics |
CA3224408A1 (en) * | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120269826A1 (en) * | 2009-10-20 | 2012-10-25 | Mckee Charlotte | Anti-cd3 antibody dosing in autoimmune disease |
WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
-
2020
- 2020-04-08 CN CN202080027728.7A patent/CN113728009A/zh active Pending
- 2020-04-08 MX MX2021012263A patent/MX2021012263A/es unknown
- 2020-04-08 EP EP20787350.6A patent/EP3953391A1/en not_active Withdrawn
- 2020-04-08 CA CA3136255A patent/CA3136255A1/en active Pending
- 2020-04-08 BR BR112021020265A patent/BR112021020265A2/pt not_active Application Discontinuation
- 2020-04-08 WO PCT/US2020/027140 patent/WO2020210277A1/en unknown
- 2020-04-08 AU AU2020272734A patent/AU2020272734A1/en not_active Abandoned
- 2020-04-08 SG SG11202111192TA patent/SG11202111192TA/en unknown
- 2020-04-08 US US17/601,787 patent/US20220213203A1/en not_active Abandoned
- 2020-04-08 JP JP2021559745A patent/JP2022526640A/ja active Pending
- 2020-04-08 KR KR1020217036260A patent/KR20210149807A/ko unknown
- 2020-04-09 TW TW109112076A patent/TW202104263A/zh unknown
-
2021
- 2021-10-07 IL IL287095A patent/IL287095A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210149807A (ko) | 2021-12-09 |
AU2020272734A1 (en) | 2021-11-18 |
WO2020210277A1 (en) | 2020-10-15 |
CA3136255A1 (en) | 2020-10-15 |
TW202104263A (zh) | 2021-02-01 |
IL287095A (en) | 2021-12-01 |
CN113728009A (zh) | 2021-11-30 |
JP2022526640A (ja) | 2022-05-25 |
EP3953391A1 (en) | 2022-02-16 |
US20220213203A1 (en) | 2022-07-07 |
MX2021012263A (es) | 2022-01-06 |
SG11202111192TA (en) | 2021-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021020265A2 (pt) | Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo | |
BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
PH12019502477A1 (en) | Use of anti cd70 antibody argx-10 treat acute myeloid leukemia | |
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
BR112016002198A2 (pt) | métodos de tratamento de miosite por corpos de inclusão esporádica | |
Krause et al. | Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC | |
RU2016122232A (ru) | Комбинированная терапия на основе антитела к cd20 и ингибитора втк | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
AR061122A1 (es) | Regimen de cladribina para tratar la escleorosis multiple | |
MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
MX2021004868A (es) | Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. | |
CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
MX2020012826A (es) | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). | |
MX2022001179A (es) | Formulaciones y dosificaciones para la administración de un compuesto que inhibe la proteína mcl1. | |
BR112016002311A2 (pt) | combinações de inibidor de cinase de pim | |
EA202190102A1 (ru) | Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака | |
CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
CR20190409A (es) | Anticuerpos biespecíficos anti-pd-l1-anti-tim-3 | |
MX2023006937A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. | |
BR112022012885A2 (pt) | Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit | |
SA521421988B1 (ar) | مركبات ترابطية لإنتاج 1-هكسين في عملية معالجة الإيثيلين بالأوليجومرات بمساعدة الكروم | |
MX2021010313A (es) | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. | |
BR112021008679A2 (pt) | Métodos para tratar câncer, e composição farmacêutica | |
MX2024001363A (es) | Metodos para el tratamiento de la leucemia mieloide aguda con los anticuerpos anti-ilt3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |